<DOC>
	<DOCNO>NCT00808444</DOCNO>
	<brief_summary>The purpose present study demonstrate change manufacture process commercial lot pneumococcal conjugate vaccine GSK1024850A clinical impact immune response non-inferior immune response induce clinical lot . The study conduct Singapore Malaysia .</brief_summary>
	<brief_title>Primary Vaccination Study With Pneumococcal Conjugate Vaccine Healthy Children 6-12wks Age</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female subject , include 612 week age time first vaccination . Subjects investigator believe parent ( ) /guardian ( ) comply requirement protocol . Written oral , sign thumbprinted informed consent obtain parent ( ) /guardian ( ) child/ward . Free know suspected health problem ( establish medical history clinical examination enter study ) . Born gestation period &gt; = 36 &lt; = 42 week . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Concurrently participate another clinical study , time study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . A family history congenital hereditary immunodeficiency . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . Administration immunoglobulins and/or blood product since birth plan administration study period ( exception hepatitis B immunoglobulins birth ) . Previous vaccination diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B , Haemophilus influenzae type b and/or Streptococcus pneumoniae ( exception vaccine first dose give within first two week life ) . Planned administration/administration vaccine foreseen study protocol period start 30 day dose vaccine end 7 day Dose 1 Dose 2 30 day Dose 3 . History , intercurrent diphtheria , tetanus , pertussis , hepatitis B , poliomyelitis , H. influenzae type b rotavirus disease . History allergic disease reaction likely exacerbate component vaccine . History neurological disorder seizure . Major congenital defect serious chronic illness . Acute disease time enrolment . Gastroenteritis within 7 day precede study vaccine administration . Any clinically significant history chronic gastrointestinal disease include uncorrected congenital malformation gastrointestinal tract , intussusception medical condition determine serious investigator .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Primary vaccination</keyword>
	<keyword>Safety</keyword>
	<keyword>Pneumococcal disease</keyword>
</DOC>